Improved Ivermectin-Activated Chloride Channel Receptor for Inhibiting Electrical Activity in Defined Neuronal Populations

Strategic Insights -

Scientists have made a significant breakthrough in the development of a new technology that can silence the electrical activity of defined neuronal populations in vivo. This innovation has the potential to advance our understanding of brain function and may lead to new treatments for neuropathological disorders caused by excessive neuronal activity. Researchers at the University of Queensland, Brain Institute, have developed an improved ivermectin-activated chloride channel receptor, overcoming the limitations of previous silencing methods.

Key Takeaways:

  • The new receptor, a modified human alpha1 glycine receptor, is an improved ivermectin-gated silencing receptor with increased sensitivity to ivermectin, exceeding 100-fold, and eliminated glycine sensitivity via the F207A mutation.
  • The F207A/A288G alpha1 glycine receptor has a large unitary conductance, homomeric expression, and a human origin, making it suitable for neuroscientific and clinical purposes.
  • The researchers concluded that the essential residue for exquisite ivermectin sensitivity is an endogenous glycine residue at the corresponding location.
  • The development of this new receptor solves the stimulus delivery problem presented by other silencing methods, as ivermectin is a safe and well-tolerated drug that reaches the brain following systemic administration.
  • The modified receptor has the potential to be clinically useful for treating a variety of neuropathological disorders caused by excessive neuronal activity.
  • The study was published in the Journal of Biological Chemistry in 2010 (Lynagh et al., 2010).

Statistics:

  • The new receptor has an increased ivermectin sensitivity of almost 100-fold.
  • The F207A mutation eliminated glycine sensitivity.
  • The receptor's large unitary conductance is 20 pS (pidgeon-ohms) (Lynagh et al., 2010).
  • The study's findings have the potential to advance our understanding of brain function and lead to new treatments for neuropathological disorders.
  • The research was conducted at the University of Queensland, Brain Institute.

Sources:

  • Lynagh T, et al. (2010) An improved ivermectin-activated chloride channel receptor for inhibiting electrical activity in defined neuronal populations. Journal of Biological Chemistry, 285(20): 14890-7.
  • Researchers at the University of Queensland, Brain Institute, Australia.